phenanthrenes and Hepatitis-C--Chronic

Recent emergence of direct-acting antivirals (DAAs) targeting hepatitis C virus (HCV) proteins has considerably enhanced the success of antiviral therapy. However, the appearance of DAA-resistant-associated variants is a cause of treatment failure, and the high cost of DAAs renders the therapy not accessible in countries with inadequate medical infrastructures. Therefore, the search for new inhibitors with a lower cost of production should be pursued. In this context, the crude extract of

Topics: Antiviral Agents; Cell Line; Drug Resistance, Viral; Genotype; HEK293 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Humans; Phenanthrenes; Phenethylamines; Plant Extracts; Protease Inhibitors; Replicon; Rhizome; Virus Replication

Hepatitis C virus (HCV) is the major causative agent of chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma. The recent development of highly effective direct-acting antivirals (DAAs) has revolutionized the treatment of HCV patients. However, these DAAs are exorbitantly expensive for the majority of HCV patients worldwide. Moreover, these drugs still show genotypic difference in cure rate and have some resistant-associated variants. Tylophorine, a natural compound derived from Tylophora indica plants, is known to have anti-inflammatory and anti-cancerous growth activities. In the present study, we showed that two tylophorine intermediates, 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl) methyl]-L-proline (O859585) and 2,3,6,7-tetramethoxy-9-phenanthrenecarboxylic acid (T298875), displayed anti-HCV activity with an EC

Topics: Alkaloids; Antiviral Agents; Cell Line, Tumor; Cell Survival; Drug Synergism; Drug Therapy, Combination; HEK293 Cells; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Indolizines; Interferon-alpha; Phenanthrenes; Primary Cell Culture; Proline; Sofosbuvir; Tetraspanin 28; Tylophora; Viral Envelope Proteins; Virus Internalization